Belatacept-based regimens versus a cyclosporine a-based regimen in kidney transplant recipients: 2-year results from the benefit and benefit-EXT studies

Transplantation

Volumn 90, Issue 12, 2010, Pages 1528-1535

  Larsen, Christian P ^a   Grinyó, Josep ^b   Medina Pestana, José ^c   Vanrenterghem, Yves ^d   Vincenti, Flavio ^e   Breshahan, Barbara ^f   Campistol, Josep M ^g   Florman, Sander ^h   Rial, Maria Del Carmen ⁱ   Kamar, Nassim ^j   Block, Alan ^k   Di Russo, Gregory ^k   Lin, Chen Sheng ^k   Garg, Pushkal ^k   Charpentier, Bernard ^l  

^a EMORY UNIVERSITY   (United States)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c HOSPITAL DO RIM E HIPERTENSÃO   (Brazil)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

^g UNIVERSITY OF BARCELONA   (Spain)

^h MOUNT SINAI MEDICAL CENTER   (United States)

ⁱ Instituto de Nefrologia Buenos Aires ar   (Argentina)

^j INSERM   (France)

^k BRISTOL MYERS SQUIBB   (United States)

^l BICÊTRE HOSPITAL   (France)

more..

Author keywords

Belatacept; Cyclosporine A; GFR; Kidney transplant; Survival

Indexed keywords

BELATACEPT; CYCLOSPORIN A;

ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; ARTICLE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EPSTEIN BARR VIRUS; FEMALE; FEVER; GLOMERULUS FILTRATION RATE; GRAFT DYSFUNCTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LYMPHOCELE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; URINARY TRACT INFECTION;

CYCLOSPORINE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; POSTOPERATIVE COMPLICATIONS; RISK ASSESSMENT; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 78650831358     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181ff87cd     Document Type: Article

References (25)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.
2. van den Ham EC, Kooman JP, Christiaans MH, et al. Weight changes after renal transplantation: A comparison between patients on 5-mg maintenance steroid therapy and those on steroid-free immunosuppressive therapy. Transpl Int 2003; 16: 300.
3. Hjelmesaeth J, Hartmann A, Kofstad J, et al. Tapering off prednisolone and cyclosporin the first year after renal transplantation: The effect on glucose tolerance. Nephrol Dial Transplant 2001; 16: 829.
4. Roland M, Gatault P, Doute C, et al. Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation. Transpl Int 2008; 21: 523.
5. Ducloux D, Motte G, Kribs M, et al. Hypertension in renal transplantation: Donor and recipient risk factors. Clin Nephrol 2002; 57: 409.
6. Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis 2004; 43: 1071.
7. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10: 547.
8. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).AmJ Transplant 2010; 10: 535.
9. Vincenti F, Blancho G, Durrbach A, et al. Five-year safety and efficacy of belatacept in renal transplantation. J AmSoc Nephrol 2010; 21: 1587.
10. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005; 16: 3015.
11. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4: 481.
12. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine:Areport of the FK506 Kidney Transplant Study Group. Transplantation 1998; 66: 1736.
13. Chang SG, Kim JH, Lee SJ, et al. Factors influencing contralateral renal hypertrophy after living donor nephrectomy. Transplant Proc 2002; 34: 1139.
14. Liu B, Preisig PA. Compensatory renal hypertrophy is mediated by a cell cycle-dependent mechanism. Kidney Int 2002; 62: 1650.
15. Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony study: Observational results 3 years after transplantation. Am J Transplant 2009; 9: 1876.
16. He X, Johnston A. Early acute rejection does not affect chronic allograft nephropathy and death censored graft failure. Transplant Proc 2004; 36: 2993.
17. Sijpkens YW, Doxiadis II, Mallat MJ, et al. Early versus late acute rejection episodes in renal transplantation. Transplantation 2003; 75: 204.
18. Opelz G, Daniel V, Naujokat C, et al. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma. Transplantation 2009; 88: 962.
19. Caillard S, Lelong C, Pessione F, et al. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: Report of 230 cases from the French Registry. Am J Transplant 2006; 6: 2735.
20. Shahinian VB, Muirhead N, Jevnikar AM, et al. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients. Transplantation 2003; 75: 851.
21. United States Renal Data System. USRDS 2008 annual data report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2008. Accessed November 15, 2008. Available at: http://www.usrds.org/adr.htm.
22. United States Renal Data System. USRDS 2009 annual data report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2009. Accessed November 30, 2009. Available at:http://www.usrds.org/.
23. Wilson DM, Bergert JH, Larson TS, et al. GFR determined by nonradiolabeled iothalamate using capillary electrophoresis.AmJ Kidney Dis 1997; 30: 646.
24. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461.
25. Levey AS, Coresh J, Greene T, et al. Expressing the MDRD study equation for estimating GFR with IDMS traceable (gold standard) serum creatinine values. J Am Soc Nephrol 2005; 16: 69A.